Cathay Biotech Inc.
SSE:688065.SS
52.2 (CNY) • At close April 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,957.912 | 2,114.175 | 2,441.104 | 2,197.457 | 1,497.191 | 1,916.199 | 1,757.116 | 1,362.695 | 929.128 |
| Cost of Revenue
| 2,033.667 | 1,505.425 | 1,580.841 | 1,339.864 | 748.387 | 1,061.041 | 991.899 | 768.581 | 593.36 |
| Gross Profit
| 924.245 | 608.75 | 860.263 | 857.593 | 748.804 | 855.158 | 765.217 | 594.114 | 335.769 |
| Gross Profit Ratio
| 0.312 | 0.288 | 0.352 | 0.39 | 0.5 | 0.446 | 0.435 | 0.436 | 0.361 |
| Reseach & Development Expenses
| 233.339 | 189.128 | 187.715 | 133.531 | 84.3 | 90.16 | 86.394 | 64.56 | 37.524 |
| General & Administrative Expenses
| 50.369 | 64.821 | 65.475 | 49.465 | 50.473 | 56.39 | 35.658 | 32.901 | 56.064 |
| Selling & Marketing Expenses
| 36.539 | 38.202 | 45.129 | 41.848 | 74.725 | 84.489 | 81.701 | 58.598 | 43.75 |
| SG&A
| 86.908 | 103.023 | 110.603 | 91.313 | 125.198 | 140.879 | 117.359 | 91.499 | 99.814 |
| Other Expenses
| 52.436 | -137.696 | 108.891 | 81.85 | 44.196 | 57.824 | -0.043 | -13.069 | -7.563 |
| Operating Expenses
| 372.684 | 124.932 | 407.209 | 306.695 | 253.694 | 288.862 | 252.256 | 163.23 | 141.922 |
| Operating Income
| 551.561 | 454.295 | 708.284 | 738.848 | 522.232 | 589.058 | 541.074 | 405.843 | 205.074 |
| Operating Income Ratio
| 0.186 | 0.215 | 0.29 | 0.336 | 0.349 | 0.307 | 0.308 | 0.298 | 0.221 |
| Total Other Income Expenses Net
| -3.546 | -5.371 | -12.292 | 1.098 | -1.445 | -33.189 | 1.152 | -13.069 | -7.563 |
| Income Before Tax
| 548.015 | 448.925 | 695.992 | 739.946 | 520.788 | 555.869 | 541.031 | 392.775 | 197.511 |
| Income Before Tax Ratio
| 0.185 | 0.212 | 0.285 | 0.337 | 0.348 | 0.29 | 0.308 | 0.288 | 0.213 |
| Income Tax Expense
| 73.426 | 40.389 | 83.337 | 93.262 | 63.447 | 76.989 | 74.739 | 60.047 | 52.04 |
| Net Income
| 488.962 | 366.524 | 553.266 | 594.719 | 457.672 | 478.88 | 466.293 | 332.728 | 145.47 |
| Net Income Ratio
| 0.165 | 0.173 | 0.227 | 0.271 | 0.306 | 0.25 | 0.265 | 0.244 | 0.157 |
| EPS
| 0.84 | 0.63 | 0.95 | 1.02 | 0.78 | 0.82 | 1.29 | 0.92 | 0.4 |
| EPS Diluted
| 0.84 | 0.63 | 0.95 | 1.02 | 0.78 | 0.82 | 1.29 | 0.92 | 0.4 |
| EBITDA
| 896.606 | 784.214 | 994.124 | 916.516 | 649.162 | 690.512 | 617.045 | 440.297 | 228.577 |
| EBITDA Ratio
| 0.303 | 0.371 | 0.407 | 0.417 | 0.434 | 0.36 | 0.351 | 0.323 | 0.246 |